All information below describes the compound's chemical identity, laboratory handling, and the published research literature. It describes molecular targets and results in laboratory and animal models only — not effects in humans — and is not evidence of any human benefit.
What Is CJC-1295 (No DAC)?
CJC-1295 without DAC is a synthetic 29-amino-acid peptide analogue of endogenous growth hormone-releasing hormone (GHRH), designated Modified GRF 1-29 (Mod GRF 1-29) in the research literature. It belongs to the GHRH-analogue class and corresponds to a modified form of the first 29 residues of native GHRH. Unlike the "with DAC" form of CJC-1295, which incorporates a Drug Affinity Complex (DAC) moiety enabling covalent albumin binding and an extended plasma half-life, the without-DAC form lacks that conjugation and is characterized in the literature by a relatively short plasma half-life associated with pulsatile rather than sustained signaling profiles.
It is supplied as a reference compound for in vitro and animal research use only. The sections below summarize its chemical identity, laboratory handling, the molecular targets and model systems examined in the published literature, and the primary references — without describing outcomes, efficacy, or effects in humans.
Research Targets & Pathways
Published preclinical literature has examined CJC-1295 without DAC in relation to several molecular systems. These are pathway associations reported in laboratory and animal models; refer to the cited studies for methods and findings.
- GHRH receptor — examined in relation to growth hormone-releasing hormone receptor occupancy and binding in pituitary cell models and receptor competition assays.
- Somatotropic (GH/IGF-1) axis — studied in relation to pituitary growth hormone secretion and downstream insulin-like growth factor 1 signaling.
- cAMP signaling — examined in relation to intracellular cyclic AMP accumulation downstream of GHRH receptor activation.
- Pulsatile GH secretion dynamics — investigated in relation to pulse-frequency and pulse-amplitude characteristics of growth hormone release.
- Cortisol / prolactin selectivity — examined as tolerability endpoints alongside GH response in GHRH-analogue dosing studies.
Model Systems Studied
CJC-1295 without DAC and related GHRH analogues have been used as test compounds across a range of published preclinical model systems and in vitro assays. Refer to the cited literature for study designs, endpoints, and findings.
- Pituitary cell cultures — somatotroph stimulation and GH-secretion assay systems.
- cAMP accumulation assays — cell-based readouts of GHRH receptor signaling.
- GHRH receptor binding competition assays — in vitro receptor-affinity characterization.
- Rodent models — GH-release and nocturnal-GH sleep-model systems.
- Clinical GHRH-analogue cohorts — pulsatile GH/IGF-1 sampling and body-composition endpoints reported for related GHRH analogues.
Note: direct human trials of CJC-1295 without DAC (Modified GRF 1-29) are limited; much of the referenced human data derives from related GHRH analogues rather than from this specific compound.
Molecular & Technical Profile
C149H246N44O42S | MW 3367.97 g/mol | CAS 863288-34-0 | 29-amino-acid GHRH analogue (Modified GRF 1-29)
Storage, Reconstitution & Working Concentrations
Storage, reconstitution, and working-concentration values are general laboratory guidance for in vitro and animal research; always confirm against the lot-specific Certificate of Analysis. Note: direct human trials of CJC-1295 without DAC are limited, and much referenced human data derives from related GHRH analogues.
Current Research Status
CJC-1295 without DAC (Modified GRF 1-29) has not been approved by the U.S. Food and Drug Administration (FDA) for any human therapeutic use. The material supplied by Explicit Research is a reference compound for laboratory research use only and is not an approved drug product. The available evidence base is primarily preclinical and derived from in vitro assays and animal models; where human data appear in the literature, they largely concern related GHRH analogues rather than this specific compound, and direct controlled clinical trials of CJC-1295 without DAC are limited. Ongoing research continues to characterize the compound's mechanistic profile within the GHRH receptor and somatotropic-axis pathways.
Research FAQ
Is CJC-1295 (No DAC) approved for human use?
No. CJC-1295 without DAC (Modified GRF 1-29) has not been approved by the FDA for any human therapeutic use. The material supplied by Explicit Research is a reference compound for laboratory research use only and is not an approved drug product — not for human consumption.
What is CJC-1295 (No DAC)'s molecular formula and sequence?
A synthetic 29-amino-acid analogue of growth hormone-releasing hormone (GHRH), designated Modified GRF 1-29 — molecular formula C149H246N44O42S, MW 3367.97 g/mol, CAS 863288-34-0.
How is CJC-1295 (No DAC) stored and reconstituted?
Store lyophilized at −20°C, protected from light and moisture. Reconstitute in sterile water for injection or bacteriostatic water added slowly to the vial wall and swirled gently (do not vortex); store the reconstituted solution at 2–8°C, use within ~21 days, and avoid repeated freeze–thaw.
What targets and model systems has CJC-1295 (No DAC) been studied in?
Preclinical work has examined the GHRH receptor, the somatotropic (GH/IGF-1) axis, and cAMP signaling using pituitary cell cultures, cAMP accumulation assays, GHRH receptor binding competition assays, and rodent GH-secretion models. Note the limited-direct-data caveat noted above.
Selected References
- Jetté et al. - CJC-1295 characterized as a long-acting GHRH analog with 4-fold greater GH release amplitude and 72-hour plasma detectability vs. native GHRH in rat models - Endocrinology, 2005
- Fintini et al. - Receptor binding affinity and downstream signaling kinetics of GHRH analogs quantified in pituitary cell models - Neuroendocrinology, 2005
- Frohman et al. - Structure-activity relationships of GHRH analogs assessed by pituitary somatotroph stimulation assays - J Clin Invest, 1999
- Bowers CY - Historical review and mechanistic classification of GH secretagogue receptor ligands and their structural determinants - Methods Enzymol, 2012
- Ionescu et al. - Prolonged stimulation of GH and IGF-1 secretion measured over multiple dosing intervals in healthy adult volunteers - J Clin Endocrinol Metab, 2006
- Veldhuis et al. - Deconvolution analysis of pulsatile GH release measured by frequent blood sampling in GHRH-analog-treated adults - Eur J Endocrinol, 2009
- Veldhuis et al. - Ghrelin and GHRH shown to act on separate receptor pathways with synergistic amplification of pulsatile GH output measured in human volunteers - Am J Physiol, 2005
- Raun et al. - Ipamorelin characterized as the first selective GH secretagogue; GH pulse elevation measured without concurrent cortisol or prolactin rise - Eur J Endocrinol, 1998
- Khorram et al. - Pulsatile GH secretion and IGF-1 levels measured in aging adults following GHRH analog administration over 5 months - J Clin Endocrinol Metab, 2006
- Sigalos et al. - Serial GH measurements used to compare pulse frequency and amplitude between native GHRH and stabilized analogs in healthy male subjects - Fertil Steril, 2001
- Falutz et al. - Visceral adipose tissue volume quantified by CT scan in HIV-associated lipodystrophy patients treated with a GHRH analog over 26 weeks - J Clin Endocrinol Metab, 2008
- Koutkia et al. - IGF-1 AUC and lean body mass measured by DEXA following pulsatile GHRH analog delivery in HIV-positive subjects with fat accumulation - J Clin Endocrinol Metab, 2004
- Sattler et al. - Appendicular lean mass and IGF-1 concentrations quantified in older adults receiving GHRH analog vs. placebo over 6 months - J Gerontol A Biol Sci Med Sci, 2006
- Van Cauter et al. - Polysomnographic staging used to correlate slow-wave sleep duration with endogenous GH pulse amplitude and timing in healthy adults - Sleep, 2000
- Norman et al. - Nocturnal GH pulse magnitude and IGF-1 response quantified under GHRH-analog dosing in a rodent sleep model - Am J Physiol Regul Integr Comp Physiol, 2013
- Clemmons et al. - Euglycemic-hyperinsulinemic clamp used to assess insulin sensitivity in GH-deficient adults receiving IGF-1-elevating secretagogue therapy - J Clin Endocrinol Metab, 2009